Form SC 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0000947871-20-000855
Filing Date
2020-11-06
Accepted
2020-11-06 17:12:46
Documents
2
Group Members
ORBIMED ADVISORS ISRAEL II LTDORBIMED CAPITAL GP VII LLCORBIMED CAPITAL LLCORBIMED GENESIS GP LLCORBIMED ISRAEL GP II, L.P.

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D ss185308_sc13d.htm SC 13D 178525
2 JOINT FILING AGREEMENT ss185308_ex9901.htm EX-99.1 10876
  Complete submission text file 0000947871-20-000855.txt   191200
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

EIN.: 133976876 | State of Incorp.: DE
Type: SC 13D

Mailing Address GALECTO BIOTECH AB OLE MAALOES VEJ3 COPENHAGEN G7 DK-2200
Business Address GALECTO BIOTECH AB OLE MAALOES VEJ3 COPENHAGEN G7 DK-2200 45-70-70-52-10
Galecto, Inc. (Subject) CIK: 0001800315 (see all company filings)

EIN.: 371957007 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-91812 | Film No.: 201295285
SIC: 2834 Pharmaceutical Preparations